Long-Term Clinical Remission in Biologically Naïve Crohn’s Disease Patients with Adalimumab Therapy, Including Analyses of Switch from Adalimumab to Infliximab

Publisher： Karger

E-ISSN： 1662-0631|10|2|283-291

ISSN： 1662-0631

Source： Case Reports in Gastroenterology, Vol.10, Iss.2, 2016-06, pp. : 283-291

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical Experience with Adalimumab in a Multicenter Swiss Cohort of Patients with Crohn’s Disease

By  

Digestion, Vol. 81, Iss. 2, 2010-01 ,pp. : 78-85

Karger

Access to resources Recommend Favorite

Clinical experience with infliximab and adalimumab in a single-center cohort of patients with Crohn's disease

By Riis Åse   Martinsen Tom C.   Waldum Helge L.   Fossmark Reidar  

Scandinavian Journal of Gastroenterology, Vol. 47, Iss. 6, 2012-06 ,pp. : 649-657

Informa Healthcare

Access to resources Recommend Favorite

Long-Term Partial Remission of AutoImmune Thrombocytopenia in a Patient Treated with the Anti-Tumor Necrosis Factor-Alpha Antibody Infliximab for Refractory Fistulizing Crohn’s Disease

By  

Digestion, Vol. 78, Iss. 4, 2008-12 ,pp. : 195-200

Karger

Access to resources Recommend Favorite

Endoscopic Severity Predicts Long-Term Prognosis in Crohn's Disease Patients with Clinical Remission

By  

Digestion, Vol. 93, Iss. 1, 2016-0 ,pp. : 66-71

Karger

Access to resources Recommend Favorite

Combination Therapy with Intensive Granulocyte and Monocyte Adsorptive Apheresis plus Adalimumab: Therapeutic Outcomes in 5 Cases with Refractory Crohn’s Disease

By  

Case Reports in Gastroenterology, Vol. 6, Iss. 3, 2012-12 ,pp. : 765-771

Karger

Access to resources Recommend Favorite